38 research outputs found

    PreocupaçÔes sobre a recorrĂȘncia do cĂąncer em mulheres mexicanas sobreviventes do cĂąncer de mama. Propriedades psicomĂ©tricas da escala CARS

    Get PDF
    Fear of recurrence is one of the main affectations of cancer survivors. In Latin-American exist a lack of evidence on the subject and of valid instruments to measure it. The objective of this study was to determine the psychometric properties of the Concerns About Recurrence Scale in Mexican breast cancer survivors. An instrumental study was carried out with 200 women breast cancer survivors with a mean age of 53 years old and a mean survival of 52.5 months. A confirmatory factor analysis of the original version of the scale identified four factors that explained 77 % of the variance and satisfactory goodness of fit indicators: CFI = .967, TLI = .957, SRMR = .035, RMSEA = .071 as well as high internal consistency α = .945. Significant associations were also identified between general fear subscale, anxiety subscale of the HADS and total HADS score (r = .638 and r = .607; p = .01). The CARS presented adequate validity, reliability and factorial structure. It is recommended for usage in clinical care and research with Mexican breast cancer survivors.El miedo a la recurrencia es una de las principales afectaciones de los supervivientes de cĂĄncer. En AmĂ©rica Latina existe una falta de evidencia en el tema y de instrumentos vĂĄlidos para medirlo. El objetivo del presente estudio fue determinar las propiedades psicomĂ©tricas de la Escala de Preocupaciones Acerca del CĂĄncer (CARS, por su sigla en inglĂ©s) en supervivientes de cĂĄncer de mama mexicanas. Se llevĂł a cabo un estudio instrumental con 200 mujeres supervivientes de cĂĄncer mamario con una edad promedio de 53 años y una sobrevida promedio de 52.5 meses. Un anĂĄlisis factorial confirmatorio de la versiĂłn original del instrumento identificĂł cuatro factores que explicaron el 77 % de la varianza de la escala e indicadores de bondad de ajuste satisfactorios: CFI = .967, TLI = .957, SRMR = .035, RMSEA = .071, asĂ­ como una elevada consistencia interna α = .945. Asimismo, se identificaron asociaciones significativas entre las subescalas de miedo general, ansiedad de la HADS y puntaje total de la HADS (r = .638 y r = .607; p = .01). La escala CARS presentĂł adecuada validez, confiabilidad y estructura factorial. Es recomendable su uso en escenarios clĂ­nicos y de investigaciĂłn con supervivientes de cĂĄncer de mama mexicanas.O medo da recorrĂȘncia Ă© uma das principais sequelas dos sobreviventes do cĂąncer. Na AmĂ©rica Latina hĂĄ uma falta de evidĂȘncias sobre o assunto e uma falta de instrumentos vĂĄlidos para medi-lo. O objetivo do presente estudo foi determinar as propriedades psicomĂ©tricas da Escala PreocupaçÔes sobre o CĂąncer (CARS) em sobreviventes do cĂąncer de mama mexicanas. Foi realizado um estudo instrumental com 200 mulheres sobreviventes de cĂąncer de mama com uma mĂ©dia de idade de 53 anos e uma sobrevivĂȘncia mĂ©dia de 52,5 meses. Uma anĂĄlise fatorial confirmatĂłria da versĂŁo original do instrumento identificou quatro fatores que explicaram 77 % da variação da escala e indicadores satisfatĂłrios de bondade de ajuste: CFI = 0,967, TLI = 0,957, SRMR = 0,035, RMSEA = 0,071, assim como alta consistĂȘncia interna α = 0,945. AssociaçÔes significativas tambĂ©m foram identificadas entre as subescalas de medo geral, ansiedade HADS e pontuação total HADS (r = 0,638 e r = 0,607; p = 0,01). A escala CARS mostrou adequada validade, confiabilidade e estrutura de fatores. É recomendado seu uso em ambientes clĂ­nicos e de pesquisa com sobreviventes do cĂąncer de mama mexicanas

    Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Despite broad advances in multimodal treatment of locally advanced breast cancer (LABC), 30 to 40% of patients develop loco-regional relapse. The aim of this study was to analyze in a retrospective manner the effectiveness of concurrent chemo-radiotherapy (CCRTh) after neoadjuvant chemotherapy (NCT) in patients with LABC.</p> <p>Methods</p> <p>One hundred twelve patients with LABC (stage IIB-IIIB) were treated with NCT (5-fluorouracil 500 mg/m<sup>2</sup>, doxorubicin 50 mg/m<sup>2</sup>, and cyclophosphamide 500 mg/m<sup>2 </sup>(FAC), or doxorubicin 50 mg/m<sup>2 </sup>and cyclophosphamide 500 mg/m<sup>2 </sup>(AC) IV in four 21-day courses) followed by CCRTh (60 Gy breast irradiation and weekly mitomycin 5 mg/m<sup>2</sup>, 5-fluorouracil 500 mg/m<sup>2</sup>, and dexamethasone 16 mg, or cisplatin 30 mg/m<sup>2</sup>, gemcitabine 100 mg/m<sup>2 </sup>and dexamethasone 16 mg), and 6–8 weeks later, surgery and two additional courses of FAC, AC, or paclitaxel 90 mg/m<sup>2 </sup>weekly for 12 weeks, and in case of estrogen-receptor positive patients, hormonal therapy.</p> <p>Results</p> <p>Stages IIB, IIIA and -B were 21.4, 42.9, and 35.7%, respectively. Pathological complete response (pCR) in the breast was 42% (95% CI, 33.2–50.5%) and, 29.5% (95% CI, 21.4–37.5%) if including both the breast and the axillary nodes. Multivariate analysis showed that the main determinant of pCR was negative estrogen-receptor status (HR = 3.8; 95% CI, 1.5–9; <it>p </it>= 0.016). The 5-year disease-free survival (DFS) was 76.9% (95% CI, 68.2–84.7%). No relationship between pCR and DFS was found. Multivariate analysis demonstrated that the main DFS determinant was clinical stage (IIB and IIIA <it>vs. </it>IIIB, HR = 3.1; 95% CI, 1.02–9.74; <it>p </it>= 0.04). Only one patient had local recurrence. Five-year overall survival was 84.2% (95% CI, 75–93.2%). The toxicity profile was acceptable.</p> <p>Conclusion</p> <p>This non-conventional multimodal treatment has good loco-regional control for LABC. Randomized clinical trials of preoperative CCRTh following chemotherapy, in patients with LABC are warranted.</p

    The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2−) breast cancer::When might multigene assays be of value?

    Get PDF
    A modest proportion of patients with early stage hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer benefit from adjuvant chemotherapy. Traditionally, treatment recommendations are based on clinical/pathologic criteria that are not predictive of chemotherapy benefit. Multigene assays provide prognostic and predictive information that can help to make more informed treatment decisions. The MAGIC survey evaluated international differences in treatment recommendations, how traditional parameters are used for making treatment choices, and for which patients treating physicians feel most uncertain about their decisions

    Full-Exon Pyrosequencing Screening of BRCA Germline Mutations in Mexican Women with Inherited Breast and Ovarian Cancer

    Get PDF
    Hereditary breast cancer comprises 10% of all breast cancers. The most prevalent genes causing this pathology are BRCA1 and BRCA2 (breast cancer early onset 1 and 2), which also predispose to other cancers. Despite the outstanding relevance of genetic screening of BRCA deleterious variants in patients with a history of familial cancer, this practice is not common in Latin American public institutions. In this work we assessed mutations in the entire exonic and splice-site regions of BRCA in 39 patients with breast and ovarian cancer and with familial history of breast cancer or with clinical features suggestive for BRCA mutations by massive parallel pyrosequencing. First we evaluated the method with controls and found 41–485 reads per sequence in BRCA pathogenic mutations. Negative controls did not show deleterious variants, confirming the suitability of the approach. In patients diagnosed with cancer we found 4 novel deleterious mutations (c.2805_2808delAGAT and c.3124_3133delAGCAATATTA in BRCA1; c.2639_2640delTG and c.5114_5117delTAAA in BRCA2). The prevalence of BRCA mutations in these patients was 10.2%. Moreover, we discovered 16 variants with unknown clinical significance (11 in exons and 5 in introns); 4 were predicted as possibly pathogenic by in silico analyses, and 3 have not been described previously. This study illustrates how massive pyrosequencing technology can be applied to screen for BRCA mutations in the whole exonic and splice regions in patients with suspected BRCA-related cancers. This is the first effort to analyse the mutational status of BRCA genes on a Mexican-mestizo population by means of pyrosequencing

    Concerns about cancer recurrence in Mexican women breast cancer survivors. Psychometric properties of the CARS scale

    Get PDF
    Fear of recurrence is one of the main affectations of cancer survivors. In Latin-American exist a lack of evidence on the subject and of valid instruments to measure it. The objective of this study was to determine the psychometric properties of the Concerns About Recurrence Scale in Mexican breast cancer survivors. An instrumental study was carried out with 200 women breast cancer survivors with a mean age of 53 years old and a mean survival of 52.5 months. A confirmatory factor analysis of the original version of the scale identified four factors that explained 77 % of the variance and satisfactory goodness of fit indicators: CFI = .967, TLI = .957, SRMR = .035, RMSEA = .071 as well as high internal consistency α = .945. Significant associations were also identified between general fear subscale, anxiety subscale of the HADS and total HADS score (r = .638 and r = .607; p = .01). The CARS presented adequate validity, reliability and factorial structure. It is recommended for usage in clinical care and research with Mexican breast cancer survivors

    The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?

    No full text
    A modest proportion of patients with early stage hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer benefit from adjuvant chemotherapy. Traditionally, treatment recommendations are based on clinical/pathologic criteria that are not predictive of chemotherapy benefit. Multigene assays provide prognostic and predictive information that can help to make more informed treatment decisions. The MAGIC survey evaluated international differences in treatment recommendations, how traditional parameters are used for making treatment choices, and for which patients treating physicians feel most uncertain about their decisions.status: publishe
    corecore